Clinical Trial Update: Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of tabalumab (LY2127399) in Japanese patients with relapsed or refractory multiple myeloma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tabalumab (tabalumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2019-03-20